

AMENDMENTS, hra (HEALTH RESEARCH AUTHORITY) WICKHAM, Alex (IMPERIAL COLLEGE HEALTHCARE NHS TRUST);Cameron.Berg@uclh.nhs.uk;info@i-hype.org;d.martin@ucl.ac.uk;'RandD@uclh.nhs.uk';

Dear Alex,

<b>IRAS Project ID:</b>	186097
<b>Short Study Title:</b>	Intraoperative Hypotension in Elder Patients (IHypE)
<b>Date complete amendment submission received:</b>	07/11/2016
<b>Amendment No./ Sponsor Ref:</b>	Non Substantial Amendment 2 - 07/11/2016
<b>Amendment Date:</b>	07/11/2016
<b>Amendment Type:</b>	Non-substantial

Thank you for submitting the above referenced amendment. In line with the [UK Process for Handling UK Study Amendments](#) I can confirm that this amendment has been categorised as:

- **Category B** - An amendment that has implications for, or affects, SPECIFIC participating NHS organisations

You should now provide this email, together with the amended documentation, to the research management support offices **and** local research teams at your participating NHS organisations in England that are affected by this amendment.

If you have participating NHS organisations in Northern Ireland, Scotland and/or Wales that are affected by this amendment, you should communicate directly with the relevant research teams to prepare them for implementing the amendment, as per the instructions below. You do not need to provide this email or your amended documentation to their research management support offices, as we will pass these to the relevant national coordinating functions who will do this on your behalf.

Subject to the four conditions below, you will be able to implement the amendment at affected participating NHS organisations in England **35 days after you notify them of the amendment**. A template email to notify participating NHS organisations in England is provided [here](#).

- You may not implement this amendment until and unless you receive all required regulatory approvals, including REC favourable opinion where applicable, (for participating organisations in England, please see 'Confirmation of Assessment Arrangements' below). You should provide regulatory approvals to the research management support offices and local research teams at your participating NHS organisations in England that are affected by this amendment, plus to local

research teams at any affected participating NHS organisations in Northern Ireland, Scotland or Wales\*.

- You may not implement this amendment at any participating NHS organisations which inform you within the 35 day period that they require additional time to consider the amendment, until they notify you that the considerations have been satisfactorily completed.
- You may not implement this amendment at any participating NHS organisation that informs you that it is no longer able to undertake this study.
- For amendments adding new sites, you may not commence research activities at site until the nation specific processes to allow this are concluded, e.g. NHS Permission in Northern Ireland, Scotland or Wales and Confirmation of capacity and capability in England (if this amendment adds new sites in England, the HRA will shortly provide further information on expectations relating to their formal confirmation of capacity and capability).

**Note:** you may only implement changes described in the amendment notice or letter.

If you receive required regulatory approvals (for participating organisations in England, please see 'Confirmation of Assessment Arrangements' below) after the 35 days have passed you may then immediately implement this amendment at all existing participating NHS organisations that have not requested additional review time, or are no longer able to undertake this study. As above, the 35 days does not apply to opening new sites and nation specific processes should be followed.

For existing participating organisations, there is no need for you to receive a letter of confirmation from the participating organisation that the amendment can be implemented, as the intended date of implementation is communicated through the above process. However, you may be able to implement this amendment ahead of the 35 day deadline, if all necessary regulatory approvals are in place and the participating organisation has confirmed that the amendment may be implemented ahead of the 35 day date.

## **Participating NHS Organisations in England – Confirmation of Assessment Arrangements**

### **Further to the details above, I can confirm that no HRA assessment of this amendment is needed.**

- If this study has HRA Approval, this amendment may be implemented at participating NHS organisations in England once the conditions detailed in the categorisation section above have been met
- If this study is a pre-HRA Approval study, this amendment may be implemented at participating NHS organisations in England that have NHS Permission, once the conditions detailed in the categorisation section above have been met. For participating NHS organisations in England that do not have NHS Permission, these sites should be covered by HRA Approval before the amendment is implemented at them, please see below;
- If this study is awaiting HRA Approval, I have passed your amendment to my colleague in the assessment team and you should receive separate notification that the study has received HRA Approval, incorporating approval for this amendment.

Please do not hesitate to contact me if you require further information.

Kind regards

Jade

Jade Robinson | Amendment Coordinator – North East REC Centre  
**Health Research Authority**  
Room 001. Jarrow Business Centre, Rolling Mill, Jarrow, Tyne & Wear

If you have any queries please email the address below:

E: [hra.amendments@nhs.net](mailto:hra.amendments@nhs.net) | T: 0207 104 8089

[www.hra.nhs.uk](http://www.hra.nhs.uk)

**IMPORTANT** – [Click here](#) for details of significant changes to the REC booking and submission process

The HRA is keen to know your views on the service you received – our short feedback form is available [here](#)

*If your email is regarding a formal request for information under the Freedom of Information Act, please resend to [HRA.FOI@nhs.net](mailto:HRA.FOI@nhs.net) to ensure it is dealt with promptly*

 Help save paper - do you need to print this email?

**Disclaimer:**

This email (and any files transmitted with it) is intended for the addressee(s) only. It may contain confidential information and may be protected by law as a legally privileged document and copyright work; its content should not be disclosed, forwarded or copied. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this e-mail is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received.

Information contained in this e-mail may be subject to public disclosure under the Freedom of Information Act 2000 or the Environmental Information Regulations 2004. Unless the information is legally exempt from disclosure, the confidentiality of this e-mail and your reply cannot be guaranteed. The HRA will not accept any liability for damage caused by computer viruses emanating from any attachment or other document supplied with this e-mail. All e-mail communications may be subject to recording and / or monitoring in accordance with relevant legislation.